Avecho Biotechnology Limited (ASX:AVE) is approaching Phase III result interim analysis of its pivotal insomnia trial for TPM-enhanced CBD capsules (late-June 2026). The product has the potential to be the first TGA-approved over-the-counter CBD-based insomnia treatment with potential for other use-cases over the medium-term.
Homodeus research hosted Avecho CEO Paul Gavin for a webinar. The video is available here.
- Phase III asset at an early-stage price right before the result. Avecho is capped at ~A$50M going into a make-or-break Phase III interim readout (late June 2026). The trial is built to maximise its odds — over-recruited, two independent endpoints where only one needs to hit, and a placebo run-in that removes the trial deficiencies that plagued prior competitors.
- Validated by a tier-one partner, pre-data. Avecho's product has had it's Australian rights licensed by Sandoz (SWX: SDZ, mkt cap ~$36bn) the world's largest generics company — before any results. Sandoz also has a global right of first refusal providing external commercial validation and a ready-built route to market.
- Regulatory backing: TGA is incentivising proper drug development to prove CBD works and is safe to close loopholes in current medicinal cannibis distribution. TGA's pathway would allow OTC CBD sales with no prescription if the trial passes — and Avecho is the last company standing in that race, patent-protected to 2043. This is a large addressable market (>US$125M/yr in Australia, US$5B+ global insomnia), with US/EU/China 10–30× bigger.
Financials and Risks
Cash position: pro-forma cash of ~A$6.6m. Phase III completion may be funded by an ex-Australian licensing agreement; equity remains an alternative
- Upside Catalysts: Licensing discussions remain active across multiple jurisdictions. Potential blue-sky for other use-cases including anxiety and pain relief. Success in Australia could materially accelerate the US registration path as the FDA have indicated they may accept the Australian trial.
- Downside Risks: Clinical failure or futility, regulatory non-approval, future funding requirements, partner dependence and commercial adoption.
